51 results
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
2 May 24
Lexicon Pharmaceuticals Reports First Quarter 2024
4:07pm
, both in our commercial launch and in our deep and innovative research and development pipeline,” said Lonnel Coats, Lexicon’s chief executive officer … potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
failure, while in parallel continuing the advancement of our innovative research and development pipeline.”
“In the fourth quarter, we saw continued … the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat
8-K
EX-99.2
LXRX
Lexicon Pharmaceuticals Inc
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
8 Nov 23
Lexicon Pharmaceuticals Reports Third Quarter 2023
7:22am
in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely
8-K
EX-99.1
l0cnc 6y9f34avma66
3 Aug 23
Lexicon Pharmaceuticals Reports Second Quarter 2023
4:08pm
8-K
EX-99.1
u359f hsqpu5ef
31 Jul 23
Lexicon Elects Diane E. Sullivan to Board of Directors
4:02pm
8-K
EX-99.1
rchrev
2 May 23
Lexicon Pharmaceuticals Reports First Quarter 2023
4:03pm
8-K
EX-99.1
9ibl2v80 loqujky
9 Nov 22
Lexicon Pharmaceuticals Reports Third Quarter 2022
4:05pm
8-K
EX-99.1
ecukefhj
2 Aug 22
Lexicon Pharmaceuticals Reports Second Quarter 2022
4:07pm
8-K
EX-99.2
kcu29p7m4wp3zm32zq
29 Jul 22
Lexicon Announces Proposed Public Offering of Common Stock
5:18pm
8-K
EX-99.3
ffnchyvhn7vviu2 idl
29 Jul 22
Lexicon Announces Proposed Public Offering of Common Stock
5:18pm
8-K
EX-99.1
0yqcq
29 Jul 22
Lexicon Announces Proposed Public Offering of Common Stock
5:18pm
8-K
EX-99.1
lmmicnu6jgdxrb
30 Jun 22
Lexicon Announces Positive Top-line Results from Phase 2 Proof-of-concept Study of LX9211 In Painful Diabetic Neuropathy
12:52pm
8-K
EX-99.1
9sprf20k61a eudc
5 May 22
Lexicon Pharmaceuticals Reports First Quarter 2022
6:10am
8-K
EX-99.1
ncnbv6m8xni9
17 Mar 22
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-99.1
amb4 3rn7
28 Feb 22
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Clinical Update
6:17am
8-K
EX-99.1
plnhz2
3 Nov 21
Lexicon Pharmaceuticals Reports Third Quarter 2021
4:05pm
8-K
EX-99.1
tu68mttsgg9x3
2 Aug 21
Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update
7:20am